Emergent BioSolutions (EBS) Misses Q4 EPS by 35c; Offers FY23 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Emergent BioSolutions Reports Financial Results for Fourth Quarter 2022
February 27, 2023 4:42 PM ESTReports Q4 2022 total revenues of $331M resulting in FY 2022 total revenues of $1,121M, in line with prior guidanceReports Q4 2022 net loss of $88M and FY 2022 net loss of $224MReports Q4 2022 adjusted EBITDA of $34M and FY 2022 adjusted EBITDA of $26M, in line with prior guidanceReports Q4 2022 adjusted gross margin of 48% and FY 2022 adjusted gross margin of 41%For FY 2023, expects continued stability of revenues and further improvements in operations and normalizing of cost structure leading to guidance of total revenues of $1,150M, adjusted EBITDA of $100M, and adjusted gross margin of 43%, all at the midpoint... More
